/Danaher%20Corp_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
While Danaher has considerably trailed behind the broader market over the past 52 weeks, Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
/Humana%20Inc_%20app%20on%20phone%20-by%20rafapress%20via%20Shutterstock.jpg)
Although Humana has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue...
/Idexx%20Laboratories%2C%20Inc_%20phone%20and%20chart%20-by%20IgorGolovniov%20via%20Shutterstock.jpg)
IDEXX Laboratories has significantly outperformed the broader market in recent months, and analysts remain cautiously optimistic about the stock’s prospects.
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Despite Regeneron Pharmaceuticals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.
/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
Abbott Laboratories is expected to announce its first-quarter results this month, and analysts predict a single-digit growth in the company’s bottom-line figure.
President Trump's reciprocal tariffs have weakened U.S. consumer and business sentiment, as consumers grow uncertain about the 'chaotic' U.S. policy, according to Reuters.Global growth concerns have resurfaced...
/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
UnitedHealth Group UNH, the largest U.S. health insurer, reported mixed fourth-quarter 2024 results. It breezed past the Zacks Consensus Estimate for earnings but missed the same for revenues. UNH shares...